Dover Pharmaceuticals Private Limited
About Dover Pharmaceuticals Private Limited
Data last updated:
Dover Pharmaceuticals Private Limited is a private limited company based in Bengaluru, Karnataka, India. It operates in the power transmission and distribution services segment of the energy and power sector. It was incorporated on 21 October 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U40100KA2015PTC083584. Its GSTIN is 29AAFCD4949M1ZZ (Karnataka).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Sara Kamal and Sanah Kamal.
Its last annual general meeting (AGM) was held on 06 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bengaluru, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.87 Lakh. For the same year it recorded a net loss of ₹1.25 Cr and EBITDA of -₹7.6 Lakh (EBITDA margin -407.5%).
As per MCA filings, the company has open charges of ₹20 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressNo. 324 Golden Point 4 1st Floor Off Queens Road Cross Vasant, H Nagar, Bengaluru, Karnataka, India – 560052
- IndustryEnergy and Power, Power Transmission & Distribution Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Dover Pharmaceuticals Private Limited FY 2025 filings available
Dover Pharmaceuticals Private Limited reported revenue of ₹1.87 Lakh for FY 2025.
Financial Statement Summary of Dover Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹7.6 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹1.25 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Dover Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -407.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | •••• | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Dover Pharmaceuticals are in the company report.
Financial statements from FY 2016
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Power industry (Pharmaceuticals, Transmission and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Experon Pharmaceuticals Private Limited | ₹1.88 Lakh (FY 2025) | •••• | •••• | -51.0% | •••• | Gorakhpur, Uttar Pradesh, India |
| Hindraj Pharmaceuticals Private Limited | ₹1.88 Lakh (FY 2023) | •••• | •••• | 795.0% | •••• | Delhi, India |
| Neurosync Pharmaceuticals Private Limited | ₹1.88 Lakh (FY 2025) | •••• | •••• | •••• | Lucknow, Uttar Pradesh, India | |
| Sofitt Pharmaceuticals Private Limited | ₹1.87 Lakh (FY 2020) | •••• | •••• | •••• | Pataudi, Haryana, India | |
| Reveto Pharmaceuticals Private Limited | ₹1.87 Lakh (FY 2021) | •••• | •••• | 53.0% | •••• | Rajura, Maharashtra, India |
| Dover Pharmaceuticals Private Limited this company | ₹1.87 Lakh (FY 2025) | •••• | •••• | •••• | Bengaluru, Karnataka, India | |
| Auszug Pharmaceuticals Private Limited | ₹1.87 Lakh (FY 2018) | •••• | •••• | -85.0% | •••• | Hyderabad, Telangana, India |
| Nuvitol Pharmaceuticals Private Limited | ₹1.87 Lakh (FY 2023) | •••• | •••• | 56.0% | •••• | Bangalore, Karnataka, India |
| Culmination Pharmaceuticals Private Limited | ₹1.86 Lakh (FY 2018) | •••• | •••• | -25.0% | •••• | Kolkata, West Bengal, India |
| Kaziranga Pharmaceuticals Private Limited | ₹1.85 Lakh (FY 2023) | •••• | •••• | •••• | Kamrup, Assam, India | |
| Angelonia Pharmaceuticals Private Limited | ₹1.85 Lakh (FY 2021) | •••• | •••• | 799.0% | •••• | Patna, Bihar, India |
Peers are the five companies nearest above and the five nearest below Dover Pharmaceuticals by revenue in the Power industry (Pharmaceuticals, Transmission and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals Private Limited is audited by J G S & ASSOCIATES for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| J G S & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sara Kamal Also directs: Hiriyur Farms Private Limited, Sira Realty Private Limited, Pureblue Real Estate Pharma Private Limited and 5 more | Director | 30 Jul 2018 | 8 Years 2 Months | Current |
| Sanah Kamal Also directs: Hiriyur Farms Private Limited, Sira Realty Private Limited, Pureblue Real Estate Pharma Private Limited and 5 more | Director | 24 Aug 2022 | 4 Years 1 Months | Current |
| Sabah Kamal Also directs: Hiriyur Farms Private Limited, Sira Realty Private Limited, Pureblue Real Estate Pharma Private Limited and 2 more | Director | 24 Aug 2022 | 4 Years 1 Months | Current |
Ownership and Shareholding of Dover Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Dover Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Aug 2024 | Others | ₹20 Cr | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Dover Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Dover Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals has one previous CIN (Corporate Identification Number): U24100KA2015PTC083584. The current CIN is U40100KA2015PTC083584, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U40100KA2015PTC083584 | Current |
| U24100KA2015PTC083584 | Previous |
Recent Activity on Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals Private Limited has 10 board changes on record since 2018: 3 appointments and 7 cessations. The latest: Sabah Kamal ceased to be Additional Director on 26 Sep 2022.
2 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Dover Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Dover Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Dover Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAFCD4949M1ZZ | Karnataka | Active | 28 Jun 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Dover Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dover Pharmaceuticals Private Limited
Dover Pharmaceuticals is an active private limited company based in Bengaluru, Karnataka, India. The company works in power transmission and distribution services, within the energy and power industry. It was incorporated on 21 October 2015 (11+ years old) and is registered under CIN U40100KA2015PTC083584.
Dover Pharmaceuticals reported revenue of ₹1.87 Lakh for FY 2025.
Dover Pharmaceuticals has 3 current directors:
- Sara Kamal - Director
- Sanah Kamal - Director
- Sabah Kamal - Director
Dover Pharmaceuticals reported a net loss of ₹1.25 Cr and EBITDA of -₹7.6 Lakh (EBITDA margin -407.5%) for FY 2025, as per its filed financial statements.
The GSTIN of Dover Pharmaceuticals is 29AAFCD4949M1ZZ, registered in Karnataka.
The CIN (Corporate Identification Number) of Dover Pharmaceuticals is U40100KA2015PTC083584. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dover Pharmaceuticals was incorporated on 21 October 2015, making it 11+ years old. It is registered with the Registrar of Companies, Bangalore.
The peers of Dover Pharmaceuticals by revenue are Experon Pharmaceuticals Private Limited, Hindraj Pharmaceuticals Private Limited, Neurosync Pharmaceuticals Private Limited, Sofitt Pharmaceuticals Private Limited, Reveto Pharmaceuticals Private Limited and 5 more, all in the Power industry (Pharmaceuticals, Transmission and Distribution).
Sabah Kamal ceased to be Additional Director on 26 Sep 2022. Sanah Kamal ceased to be Additional Director on 26 Sep 2022. Sara Kamal ceased to be Director on 25 Sep 2022. Dover Pharmaceuticals has 10 board changes on record in total.
The registered office of Dover Pharmaceuticals is at No. 324 Golden Point 4 1st Floor Off Queens Road Cross Vasant, H Nagar, Bengaluru, Karnataka, India – 560052.
Dover Pharmaceuticals has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh.